Search results for "harm"

showing 10 items of 13866 documents

2019

Beside diverse therapeutic properties of palmitoylethanolamide (PEA) including: neuroprotection, inflammation and pain alleviation, prophylactic effects have also been reported in animal models of infections, inflammation, and neurological diseases. The availability of PEA as (ultra)micronized nutraceutical formulations with reportedly no side effects, renders it accordingly an appealing candidate in human preventive care, such as in population at high risk of disease development or for healthy aging. PEA’s mode of action is multi-facetted. Consensus exists that PEA’s effects are primarily modulated by the peroxisome proliferator-activated receptor alpha (PPARα) and that PEA-activated PPARα…

0301 basic medicinePalmitoylethanolamideeducation.field_of_studyGeneral NeurosciencePopulationfood and beveragesLipid metabolismLipid signalingPharmacologyLipidomeBiologyNeuroprotection03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryLipidomicsMode of actioneducation030217 neurology & neurosurgeryFrontiers in Neuroscience
researchProduct

The Pharmacology of Visual Hallucinations in Synucleinopathies

2019

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the absence of VH in the course of the disease should raise questions about the diagnosis. VH may take the form of early and simple phenomena or appear with late and complex presentations that include hallucinatory production and delusions. VH are an unmet treatment need. The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and then discusses their pharmacological modulation. Recent models for VH have been centered on the role played by the decoupling …

0301 basic medicineParkinson's diseaseParkinson's diseaseReviewPharmacologySerotonergicdefault mode network03 medical and health sciencesGlutamatergic0302 clinical medicineDopaminemedicinePharmacology (medical)Default mode networkPharmacologySynucleinopathiesDementia with Lewy bodiesbusiness.industrylcsh:RM1-950visual hallucinationmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCholinergicSettore MED/26 - Neurologiasynucleinopathydementia with Lewy bodiesbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Parkinson's disease: towards better preclinical models and personalized treatments.

2016

Non peer reviewed

0301 basic medicineParkinson's diseaseeducationMEDLINEBioinformatics03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDEFICITSMedicineAnimalsHumansMolecular BiologyPharmacologybusiness.industryParkinson DiseaseCell Biologymedicine.diseaseMolecular medicine3. Good healthMICE030104 developmental biologyNeuroprotective AgentsCell Biology; Molecular Biology; Molecular Medicine; Pharmacology; Cellular and Molecular NeuroscienceMolecular Medicine3111 Biomedicinebusiness030217 neurology & neurosurgeryCellular and molecular life sciences : CMLS
researchProduct

Evaluation of Mucociliary Clearance by Three Dimension Micro-CT-SPECT in Guinea Pig: Role of Bitter Taste Agonists

2016

Different image techniques have been used to analyze mucociliary clearance (MCC) in humans, but current small animal MCC analysis using in vivo imaging has not been well defined. Bitter taste receptor (T2R) agonists increase ciliary beat frequency (CBF) and cause bronchodilation but their effects in vivo are not well understood. This work analyzes in vivo nasal and bronchial MCC in guinea pig animals using three dimension (3D) microCT-SPECT images and evaluates the effect of T2R agonists. Intranasal macroaggreggates of albumin-Technetium 99 metastable (MAA-Tc99m) and lung nebulized Tc99m albumin nanocolloids were used to analyze the effect of T2R agonists on nasal and bronchial MCC respecti…

0301 basic medicinePathologyPhysiologyRespiratory Systemlcsh:MedicineSingle Photon Emission Computed TomographyPharmacologyBiochemistryDiagnostic RadiologyReceptors G-Protein-CoupledMathematical and Statistical Techniques0302 clinical medicineBronchodilationMedicine and Health Scienceslcsh:ScienceTomographyLungMammalsMultidisciplinaryRadiology and ImagingDrugsfood and beveragesChloroquineAnimal Modelsrespiratory systemPulmonary ImagingBody Fluidsmedicine.anatomical_structureMucociliary ClearanceVertebratesPhysical SciencesAnatomyStatistics (Mathematics)Research ArticleAgonistmedicine.medical_specialtySingle Photon Emission Computed Tomography Computed TomographyImaging TechniquesMucociliary clearancemedicine.drug_classGuinea PigsBronchiNeuroimagingResearch and Analysis MethodsRodentsGuinea pigAntimalarials03 medical and health sciencesModel OrganismsDiagnostic MedicineIn vivoAlbuminsmedicineAnimalsHumansStatistical MethodsPharmacologyAnalysis of VarianceLungbusiness.industrylcsh:ROrganismsBiology and Life SciencesProteinsX-Ray MicrotomographyMucus030104 developmental biology030228 respiratory systemAmniotesNanoparticleslcsh:QNasal administrationbusinessMathematicsEx vivoNeuroscience
researchProduct

New insights in primary ciliary dyskinesia

2017

Introduction: Primary ciliary dyskinesia (PCD) is a rare genetic disease with an estimated prevalence of 1:20.000 births. It is characterized by abnormal motility of cilia, leading to impaired mucociliary clearance, and subsequent infection and chronic inflammation of the airways. PCD also affects spermatozoa and cilia in the Fallopian tubes, contributing to fertility issues; dyskinesia of embryonic nodal cilia causes a random distribution of the organs. Areas covered: An overview of the history, genetics, clinical manifestations in children and adults, diagnostic tests, treatments, and prognosis are reviewed. We also discuss current research and future prospects of PCD. Expert opinion: As …

0301 basic medicinePathologymedicine.medical_specialtyDiagnostic methodsbusiness.industryHealth PolicyCiliumMotilityClinical featuresDiseaseDiagnostic methodsmedicine.disease03 medical and health sciencesPrimary ciliary dyskinesia030104 developmental biology0302 clinical medicine030228 respiratory systemGeneticsotorhinolaryngologic diseasesmedicinePharmacology (medical)TherapybusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)Primary ciliary dyskinesia
researchProduct

Cystic fibrosis treatment: targeting the basic defect

2017

ABSTRACTIntroduction: Cystic Fibrosis (CF) is a disease caused by different class mutations in the CF transmembrane conductance regulator (CFTR) gene. It can therefore benefit from a personalized medicine approach based on the individual genotype of each patient.Areas covered: This review provides a detailed overview of the current major development of new CF treatments that target the basic CF defect. The review summarizes gene therapy, mRNA repair strategies, read-through agents, and CFTR-modulators (potentiators, correctors, stabilizers, amplifiers and different combination therapies).Expert opinion: We are currently perhaps at the most exciting stage in the history of CF, with the poten…

0301 basic medicinePathologymedicine.medical_specialtyMutationCombination therapybusiness.industryHealth PolicyGenetic enhancementDiseasePotentiatorBioinformaticsmedicine.diseasemedicine.disease_causeCystic fibrosisIvacaftor03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemMedicinePharmacology (medical)Personalized medicinebusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)medicine.drugExpert Opinion on Orphan Drugs
researchProduct

Distribution of macrophages and plasma cells in apical periodontitis and their relationship with clinical and image data

2017

BACKGROUND Macrophages and plasma cells play a key role in the regulation of innate and adaptive immunity. The aim of this study was to assess the presence of these cells in apical periodontitis and their distribution comparing with clinical and image data. MATERIAL AND METHODS Thirty-three lesions were selected and divided in two groups (17 periapical cysts and 16 periapical granulomas). Immunoreactions using anti-CD68 and anti-CD138 antibodies were carried out; image analysis was performed with an optical microscope and 5 high-power fields from each slide were evaluated leading to an average score of immunoexpression. This mean score was compared between the two groups and correlated with…

0301 basic medicinePathologymedicine.medical_specialtyPeriapical cystPeriapical GranulomaOperative Dentistry and Endodontics03 medical and health sciences0302 clinical medicineMedicineDistribution (pharmacology)General DentistryPeriodontitisbiologybusiness.industryCD68ResearchSignificant difference030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseAcquired immune system030104 developmental biologyUNESCO::CIENCIAS MÉDICASbiology.proteinAntibodybusinessJournal of Clinical and Experimental Dentistry
researchProduct

Drug Distribution to Retinal Pigment Epithelium: Studies on Melanin Binding, Cellular Kinetics, and Single Photon Emission Computed Tomography/Comput…

2016

Melanin binding is known to affect the distribution and elimination of ocular drugs. The purpose of this study was to evaluate if the extent of drug uptake to primary retinal pigment epithelial (RPE) cells could be estimated based on in vitro binding studies with isolated melanin and evaluate the suitability of single photon emission computed tomography/computed tomography (SPECT/CT) in studying pigment binding in vivo with pigmented and albino rats. Binding of five compounds, basic molecules timolol, chloroquine, and nadolol and acidic molecules methotrexate and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF), was studied using isolated melanin from porcine choroid-RPE at pH 5.0 and 7.4. The…

0301 basic medicinePathologymedicine.medical_specialtySingle Photon Emission Computed Tomography Computed TomographySwinePigment bindingPharmaceutical ScienceTimololRetinal Pigment EpitheliumBiologySingle-photon emission computed tomographyEye030226 pharmacology & pharmacyIodine RadioisotopesMelanin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoDrug DiscoverymedicineAnimalsDistribution (pharmacology)Cells CulturedMelaninsRetinal pigment epitheliummedicine.diagnostic_testChloroquineRetinalHydrogen-Ion Concentrationeye diseasesRats3. Good healthKineticsNadololMethotrexate030104 developmental biologymedicine.anatomical_structurechemistryTimololBiophysicsMolecular Medicinesense organsProtein Bindingmedicine.drugMolecular Pharmaceutics
researchProduct

2017

Recently, in vitro anti-cancer properties of beauvericin, a fungal metabolite were shown in various cancer cell lines. In this study, we assessed the specificity of this effect by comparing beauvericin cytotoxicity in malignant versus non-malignant cells. Moreover, we tested in vivo anticancer effects of beauvericin by treating BALB/c and CB-17/SCID mice bearing murine CT-26 or human KB-3-1-grafted tumors, respectively. Tumor size and weight were measured and histological sections were evaluated by Ki-67 and H/E staining as well as TdT-mediated-dUTP-nick-end (TUNEL) labeling. Beauvericin levels were determined in various tissues and body fluids by LC-MS/MS. In addition to a more pronounced …

0301 basic medicinePathologymedicine.medical_specialtyTUNEL assayColorectal cancerHealth Toxicology and MutagenesisPharmacologyBiologyToxicologymedicine.diseaseBeauvericinIn vitroStaining03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryIn vivoApoptosis030220 oncology & carcinogenesismedicineCytotoxicityToxins
researchProduct

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

2017

International audience; T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatm…

0301 basic medicinePediatricsmedicine.medical_specialtymedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/CancerPrecursor T-Cell Lymphoblastic Leukemia-LymphomachemotherapyGeneral Biochemistry Genetics and Molecular Biology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences[ MATH.MATH-AP ] Mathematics [math]/Analysis of PDEs [math.AP][SDV.CAN] Life Sciences [q-bio]/CancerMaintenance therapythymusT-cell lymphoblastic lymphomamedicineHumanscancer[MATH.MATH-AP]Mathematics [math]/Analysis of PDEs [math.AP]Computer Simulationmathematical modelling[MATH.MATH-AP] Mathematics [math]/Analysis of PDEs [math.AP]educationrandomized controlled clinical trialGeneral Environmental SciencePharmacologyChemotherapyeducation.field_of_studyGeneral Immunology and Microbiologybusiness.industryApplied MathematicsGeneral NeuroscienceLymphoblastic lymphomaCancerGeneral MedicineModels Theoreticalmedicine.disease3. Good healthLymphomaSurgeryClinical trial030104 developmental biologyModeling and SimulationCohortDisease ProgressionbusinessMathematical Medicine and Biology
researchProduct